Tumours that had been exposed to Celecoxib again showed a significantly decreased staining for COX-2 protein expression (median control 26.6% (IQR 12.0–32.4), treated 9.4% (IQR 3.9–18.1) (Table 1)). This evidence concerns the gene PTGS2 and neoplasm.